IPGA09:A potential First-in-class antagonist antibody for autoimmune diseases


TARGET is a chemokine receptor primarily expressed in immune cells, particularly Th17 cells, and is involved in regulating immune cell recruitment and the development of autoimmune diseases, including atopic dermatitis. IPGA09 is an antibody specifically designed to target and potentially slow down the progression of diseases.

Mechanism of Action


■IPGA09 inhibits the migration of immune cells, specifically Th17 cells, towards inflammatory lesions.

■ IPGA09 shows strong potential for suppressing autoimmune diseases, including dermatitis, by reducing immune cell infiltration and cytokine release.